ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Preparation of a controlled release chitosan transdermal patch loaded by ciprofloxacin/zinc oxide nanoparticles for cutaneous wound healing in rat.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wound Healing Potential of Multifunctional Nanomaterials: Mechanism, Future Prospects, and Challenges.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective wound healing requires materials that modulate inflammation, enhance tissue regeneration, and promote re-epithelialization. In this study, we developed and evaluated the wound healing efficacy of controlled-release chitosan-based transdermal patches loaded with ciprofloxacin and zinc nanoparticles in rats. Full-thickness excisional wounds (2 cm diameter) were created on 75 Wistar rats, assigned to five groups: chitosan (Cs), Cs-ciprofloxacin (CsCi), Cs-zinc (CsZn), Cs-ciprofloxacin-zinc (Cs/Zn@Ci), and untreated control. Tissue samples were collected on days 7, 14, and 21 for histopathological, immunohistochemical, and biochemical analysis. The Cs/Zn@Ci group exhibited significantly enhanced wound closure, approximately 1.8-, 1.54-, and 1.19-fold greater than the control at each respective time point (P < 0.05). The Cs/Zn@Ci-treated group showed marked modulation of inflammation, enhanced fibroplasia and angiogenesis, and improved scar tissue formation in the early phase. Long-term treatment resulted in improved collagen alignment, reduced scar formation, and enhanced epithelial regeneration. Gene expression analysis showed significantly elevated CK14 and EGFR levels in the Cs/Zn@Ci group compared to control, with fold increases ranging from 1.1 to 1.6 across time points (P < 0.05). Additionally, collagen and glycosaminoglycan content were markedly higher in the Cs/Zn@Ci groups throughout the healing phases. These findings demonstrate that Cs/Zn@Ci patches act synergistically to enhance healing through antimicrobial activity, immunomodulation, and matrix regeneration. This novel formulation holds strong clinical potential for improving outcomes in cutaneous wound management.
Indexed as
Identifiers
40650734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.